Yüklüyor......
The evolving treatment paradigm in myelofibrosis
Myelofibrosis (MF) is a BCR–ABL1-negative myeloproliferative neoplasm diagnosed de novo or developed from essential thrombocythemia (ET) or polycythemia vera (PV). Average survival of a patient with MF is 5–7 years. Disease complications include fatigue, early satiety, pruritus, painful splenic infa...
Kaydedildi:
| Yazar: | |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Informa Healthcare
2013
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3545544/ https://ncbi.nlm.nih.gov/pubmed/22793267 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2012.710905 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|